Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer

Program Goals

Distribution of Breast Cancer Subtypes at Diagnosis by Age

Hormonal Therapy for Advanced Breast Cancer: Milestones

Diagnosis and Treatment of HR+ mBC

Cyclin-Dependent Kinases and Cell Cycle Progression

CDK 4/6 Inhibition Is Most Effective in ER+/Luminal Breast Cancer Cells

Efficacy of First-Line Endocrine Therapy

PALOMA-3: Palbociclib and Fulvestrant, Phase 3 (Interim Study Analysis, N = 521)

Ongoing Studies With CDK 4/6 Inhibitors

PALOMA-1: Design

PALOMA-1/TRIO-18: Progression-free Survival

Palbociclib

Combination of Palbociclib + Letrozole: Dosing and Administration

Most Common Treatment-Related AEs ≥ 10%

CDK 4/6 Inhibition: Adverse Effects

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)